IRIS
PELUSO, ANNA LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 301
EU - Europa 144
NA - Nord America 84
SA - Sud America 17
AF - Africa 3
Totale 549
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 134
SG - Singapore 75
CN - Cina 70
US - Stati Uniti d'America 70
KR - Corea 64
IL - Israele 60
HK - Hong Kong 17
BR - Brasile 15
MX - Messico 14
VN - Vietnam 9
DE - Germania 6
AR - Argentina 2
EG - Egitto 2
ID - Indonesia 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
IN - India 1
JP - Giappone 1
MA - Marocco 1
NL - Olanda 1
PL - Polonia 1
SE - Svezia 1
UA - Ucraina 1
Totale 549
Salva come PNG Salva come JPEG
Città #
Singapore 74
Chicago 64
Pescara 64
Seoul 64
Rome 60
Tel Aviv 60
Hong Kong 17
Mexico City 13
Ho Chi Minh City 5
Milan 4
Hangzhou 3
Naples 2
Ajman 1
Al Mansurah 1
Allen 1
Belo Horizonte 1
Brumadinho 1
Cape Girardeau 1
Casablanca 1
Castanhal 1
Curitiba 1
Da Nang 1
Dhaka 1
Diamantino 1
Dokki 1
Dębica 1
Guajeru 1
Hanoi 1
Hidrolândia 1
Itajaí 1
La Banda 1
Mumbai 1
Osasco 1
Osório 1
Petrolina 1
Petrópolis 1
Quận Bình Thạnh 1
Rimini 1
Salvador 1
Shanghai 1
Solidaridad 1
São João da Boa Vista 1
São Lourenço 1
Thái Nguyên 1
Tokyo 1
Totale 463
Salva come PNG Salva come JPEG
Nome #
Risorse genetiche di organismi utili per il miglioramento di specie di interesse agrario e per un'agricoltura sostenibile 18
Acute and Chronic Ph+ leukemias: differential leukemogenesis pathways translate into different clinical needs 13
The A1059E mutation in Jak2 gene was detected in patients with Idiopathic Erithrocytosis secondary to Acute Lymphoblastic Leukemia 13
Frequenza delle mutazioni c-kit in pazienti affetti da Leucemia mieloide acuta (LAM) caratterizzata da alterazioni del gene del core binding factor (CBF) 12
First case of KIT Ser715del and Jak2 Val617Val mutation in systemic mastocytosis with associated essential thrombocythemia 11
Heat Shock Protein 90 (HSP90) regulates the expression of preferentially Expressed Antigen of Melanoma (PRAME) in cell lines derived from patients with Chronic Myeloid Leukemia 11
Ligh chains expression of lymphoid infiltrate in fine-needle cytology of Hashimoto's Thyroiditis 11
Caratterizzazione dei ceppi di Rhizobium spp. Simbionti di leguminose selvatiche e coltivate del climax mediterraneo 11
First case of S716del mutation in the cKIT gene and V617V mutation in Jak2 gene in a patient affected by essential thrombocytopenia associated to systemic mastocytosis 10
Increasing BCR-.ABL expression levels and/or occurrence of ABL point mutations not always predict resistance to Imatinib Mesylate in BCR-ABL positive Acute Lymphoblastic Leukemia 10
Attivazione di una immunità specifica per PRAME mediante l'utilizzo di una libreria peptidica in pazienti affetti da patologie ematologiche 10
Highly Sensitive Detection of BCR-ABL Kinase Domain Mutations in CML patients by an Ultra-Deep Sequencing Approach 10
Immunohistochemical algorithms and gene expression profiling in primary cutaneous B-cell lymphoma 10
Characterization of proteins involved in the mechanism of resistance to Imatinib Mesylate in Chronic Myeloid Leukemia 10
Unravelling the Mechanism of Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia: a Proteomic Approach 10
Immunoglobulin heavy and light chains and T-cell receptor beta and gamma chains PCR assessment on cytological samples. A study comparing FTA cards and cryopreserved lymph node fine-needle cytology 10
Clinical relevance in Chronic Myeloid Leukemia of deletion and insertion events in tyrosine kynase domain of BCR-ABL 10
A particular mutational status in a Chronic Myeloid Leukemia patient treated with different tyrosine-Kinase inhibitors 10
Clinical relevance in Chronic Myeloid Leukemia of deletion and insertion events in the tyrosine Kinase domain of BCR-ABL 10
Evaluation of proteolytic, lipolytic and decarboxylase activity of extremely halophilic bacteria occurring in ripening of salt anchovies 10
cKIT mutations frequency detected in patients with Acute Myeloid Leukemia (AML) characterized by Core Binding Factor (CBF) rearrangement 10
Clinical outcome of Chronic Myeloid Leukemia (CML) patients with deletion and Insertion events (DI) in the Tyrosine Kinase Domain of Bcr-Abl 10
Reduced levels of SHP1 provides an additive survival advantage to the Ph+ cells of CML patients and may account for resistance to Ima treatment 10
Deletion and insertion events in tyrosine Kinase domain of BCR-ABL is a common phenomenon in Chronic Myeloid Leukemia 10
Mesenchymal stem cell (MSC) derived from bone marrow (BM) of patients with Chronic Myelogenous Leukemia protect Ph+ leukemic cells from TKI induced apoptosis 10
Unravelling the mechanism of resistance to Imatinib Mesylate in Chronic Myeloid Leukemia: a proteomic approach 10
The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial 10
Biochimica ematologica in Biochimica del plasma e sistema ematopoietico 9
L'ATTIVITÀ DEGLI INIBITORI DI TIROSINA KINASI (TKI) SULLA PROLIFERAZIONE E L'ATTIVAZIONE DELLE CELLULE T 9
Characterization of Rhizobium spp.strains symbionts of wild and cultivated legumes of the Mediterranean climax 9
Cytologic, flow cytometry, and molecular assessment of lymphoid infiltrate in fine-needle cytology samples of Hashimoto thyroiditis 9
Frequencies of cKIT mutations detected in patients with Acute Myeloid Leukemia (AML) characterized by Core Binding Factor (CBF) rearrangements 9
Clonal evolution in a case of hepatosplenic T cell lymphoma 9
Use of nodulation pattern, stress tolerance, nodC gene amplification, RAPD-PCR and RFLP-16S rDNA analysis to discriminate genotypes of Rhizobium leguminosarum biovar viciae 9
Increasing BCR-ABL expression levels and/or occurrence of ABL point mutations not always predict resistance to Imatinib Mesylate in BCR-ABL positive Acute Lymphoblastic Leukemia 9
La proteina SHP-1 è implicata nella resistenza al trattamenti con Imatinib (Ima) in pazienti affetti da leucemia mieloide cronica (LMC) 9
Primo caso di trombocitemia essenziale (TE) associate a mastocitosi ossea con mutazione S715del del gene c-KIT e V616V del gene JAK2 9
The dynamics of ABL mutations onset in Ph+ Acute Lymphoblastic Leukemia treated with Imatinib Mesylate 9
Characterization of proteins involved in the mechanism of resistance to Imatinib Mesylate in Chronic Myeloid Leukemia 9
High-avidity cytotoxic lymphocytes specific for a new peotide derived from Preferentially expressed Antigen of Melanoma (PRAME) can target leukemia precursor cells 9
Decreased level of SHP-1 provides an additive survival advantage to Philadelphia Chromosome-positive (Ph+) cells derived from patients with Chronic Myeloid Leukemia (CML) and account for resistance to Imatinib (Ima) treatment 9
UNA BASSA ESPRESSIONE DELLA FOSFATASI SHP-1 CORRELA CON LA RESI-STENZA AL TRATTAMENTO CON INIBITORI DELLE TIROSIN KINASI IN PAZIENTIAFFETTI DA LEUCEMIA MIELOIDE CRONICA 9
Diversity of Rhizobium leguminosa rum biovar viciae strains nodulating wild and crop legumes in central-southern Italy 9
Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients 9
The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial 9
Effectiveness of interferon alpha therapy in essential thrombocythemia 9
The expression of shp-1 andSHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial 9
Induction of preferentially expressed antigen of melanoma (PRAME)-specific immunity by PRAME-overlapping pentadecapeptides in patients with hematologic malignancies, including chronic myelogenous leukemia 9
Cytopathology diagnosis of the thyroidal nodule: a review 9
Flow cytometric immunophenotypic and molecular profiles and follow-up in a case of gamma-delta hepatosplenic T-cell Lymphoma 9
Evalution of proteolytic, lipolytic and decarboxylase activity of extremely halophilic bacteria occurring in ripening of salt anchovies 9
Light chains expression of lymphoid infiltrate in fine-needle cytology of Hashimoto's Thyroiditis 9
The constitutive activated V617F Janus Kinase 2 (JAK2) induces centrosome abnormalities 9
The activity of tyrosine Kinase inhibitors on T-cell proliferation and activation 9
SHP1 expression accounts for resistance to Imatinib treatment in Philadelphia chromosome-positive cells derived from patients with Chronic Myeloid Leukemia 9
Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pre-treatment Predictor of Major Molecular Response Achievement in CML Patients 9
Decrease level of SHP1 provides an additive survival advantage to Philadelphia chromosome-positive (Ph+) cells derived from patients with chronic myeloid leukemia (CML) and account for resistance to Imatinib (Ima) treatment 8
Reduced levels of SHP1 provides an additive serviva advantage to the PH- cells of CML patients and may account for resistance to IMA treatment 8
Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukaemia 8
Induction of preferentially expressed antigen of melanoma (PRAME)-specific immunity by PRAME-overlapping pentadecapeptides in patients with hematologic malignancies. Including chronic myelogenous leukemia 8
Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma 8
Clinical relevance in chronic myeloid leukemia of deletion and insertion events in the tyrosine Kinase domain of BCR-ABL 8
The dynamics of ABL mutations onset in PH+ Acute Lymphoblastic Leukemia treated with Imatinib Mesylate 7
La proteina SHP-1 è implicata nella resistenza al trattamenti con Imatinib (Ima) in pazienti affetti da leucemia mieloide cronica (LMC) 7
Totale 613
Salva come PNG Salva come JPEG
Categoria #
all - tutte 4.797
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.797
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/2025329 0 0 0 64 2 4 5 126 14 0 110 4
2025/2026284 62 69 153 0 0 0 0 0 0 0 0 0
Totale 613